RU97105438A - EYE DROPS "NEOKERATONIK" - Google Patents
EYE DROPS "NEOKERATONIK"Info
- Publication number
- RU97105438A RU97105438A RU97105438/14A RU97105438A RU97105438A RU 97105438 A RU97105438 A RU 97105438A RU 97105438/14 A RU97105438/14 A RU 97105438/14A RU 97105438 A RU97105438 A RU 97105438A RU 97105438 A RU97105438 A RU 97105438A
- Authority
- RU
- Russia
- Prior art keywords
- eye drops
- sodium
- neokeratonik
- chloride
- sorbitol
- Prior art date
Links
- 229940012356 Eye Drops Drugs 0.000 title claims 3
- 239000003889 eye drop Substances 0.000 title claims 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N Taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 3
- 229960000686 Benzalkonium Chloride Drugs 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229960002989 Glutamic Acid Drugs 0.000 claims 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 2
- FVTCRASFADXXNN-MBNYWOFBSA-N [(2S,3R,4R)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-MBNYWOFBSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000012153 distilled water Substances 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000011778 trisodium citrate Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229940074453 Sodium Succinate Hexahydrate Drugs 0.000 claims 1
- 229940074404 Sodium succinate Drugs 0.000 claims 1
- 229960003080 Taurine Drugs 0.000 claims 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L disodium butanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229960002668 sodium chloride Drugs 0.000 claims 1
- ZBTUYCUNQBRXOR-UHFFFAOYSA-L sodium succinate hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-]C(=O)CCC([O-])=O ZBTUYCUNQBRXOR-UHFFFAOYSA-L 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (1)
Натрий сукцинат шестиводный - 1,91
Натрий цитрат 5,5-водный - 0,40
Сорбитол - 0,80
Натрий хлорид - 0,31
L-Глутаминовая кислота - 0,015
Рибофлавин мононуклеотидфосфат - 0,02
Бензалкония хлорид - 0,015
Вода дистиллированная для инъекций - Остальное
2. Глазные капли по п.1, отличающиеся тем, что они дополнительно содержат тауфон (таурин) в количестве 0,4 г/100 мл.1. Eye drops, including sodium succinate hexahydrate, sodium citrate 5.5-aqueous, sodium chloride, sorbitol, L-glutamic acid, riboflavin mononucleotide phosphate, benzalkonium chloride, distilled water for injection, characterized in that they additionally contain glucose in the following ratio components, wt.%:
Sodium succinate, six-water - 1.91
Sodium Citrate 5.5-Aq - 0.40
Sorbitol - 0.80
Sodium chloride - 0.31
L-Glutamic acid - 0.015
Riboflavin Mononucleotide Phosphate - 0.02
Benzalkonium chloride - 0.015
Distilled Water for Injection - Other
2. Eye drops according to claim 1, characterized in that they additionally contain taufon (taurine) in an amount of 0.4 g / 100 ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU97105438A RU2127099C1 (en) | 1997-04-07 | 1997-04-07 | Ocular drops "neokeratonik" |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU97105438A RU2127099C1 (en) | 1997-04-07 | 1997-04-07 | Ocular drops "neokeratonik" |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2127099C1 RU2127099C1 (en) | 1999-03-10 |
| RU97105438A true RU97105438A (en) | 1999-04-20 |
Family
ID=20191608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU97105438A RU2127099C1 (en) | 1997-04-07 | 1997-04-07 | Ocular drops "neokeratonik" |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2127099C1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2253321A1 (en) * | 2009-05-06 | 2010-11-24 | Roberto Pinelli | Collyrium for the treatment of conial cornea with "cross-linking" trans-epithelial technique |
| WO2011050164A1 (en) | 2009-10-21 | 2011-04-28 | Avedro, Inc. | Eye therapy |
| WO2011116306A2 (en) | 2010-03-19 | 2011-09-22 | Avedro, Inc. | Systems and methods for applying and monitoring eye therapy |
| US9044308B2 (en) | 2011-05-24 | 2015-06-02 | Avedro, Inc. | Systems and methods for reshaping an eye feature |
| WO2012167260A2 (en) | 2011-06-02 | 2012-12-06 | Avedro, Inc. | Systems and methods for monitoring time based photo active agent delivery or photo active marker presence |
| JP6271541B2 (en) | 2012-07-16 | 2018-01-31 | アヴェドロ・インコーポレーテッドＡｖｅｄｒｏ，Ｉｎｃ． | System and method for corneal cross-linking by pulsed light |
| US9498122B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
| US9498114B2 (en) | 2013-06-18 | 2016-11-22 | Avedro, Inc. | Systems and methods for determining biomechanical properties of the eye for applying treatment |
| KR102416876B1 (en) | 2014-10-27 | 2022-07-05 | 아베드로 인코퍼레이티드 | Systems and methods for cross-linking treatments of an eye |
| US10114205B2 (en) | 2014-11-13 | 2018-10-30 | Avedro, Inc. | Multipass virtually imaged phased array etalon |
| US10258809B2 (en) | 2015-04-24 | 2019-04-16 | Avedro, Inc. | Systems and methods for photoactivating a photosensitizer applied to an eye |
| EP3297589A4 (en) | 2015-05-22 | 2019-03-06 | Avedro Inc. | Systems and methods for monitoring cross-linking activity for corneal treatments |
| WO2017015471A1 (en) | 2015-07-21 | 2017-01-26 | Avedro, Inc. | Systems and methods for treaments of an eye with a photosensitizer |
| EP3827793A1 (en) | 2016-08-08 | 2021-06-02 | Avedro, Inc. | Systems and methods for cross-linking treatments of an eye |
-
1997
- 1997-04-07 RU RU97105438A patent/RU2127099C1/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU97106214A (en) | EYE DROPS "PYROTONIC" | |
| RU97105438A (en) | EYE DROPS "NEOKERATONIK" | |
| CA2201749A1 (en) | Stable aqueous alfa interferon solution formulations | |
| CA2671383A1 (en) | Dried composition | |
| FR2437406A1 (en) | SUBSTITUTED QUINOLEINECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | |
| YU23599A (en) | Stabilized antihistamine syrup | |
| DE3751871D1 (en) | Liposomes containing guanidine aminoglycoside | |
| NO843002L (en) | Aqueous solution containing a lipid-soluble pharmaceutical substance | |
| RU97110276A (en) | EYE DROPS "INTERTONIK" | |
| FR2633929B2 (en) | NON-TOXIC N-BUTYRIC ACID DERIVATIVES WITH DELAYED THERAPEUTIC ACTIONS | |
| CA2057291A1 (en) | A stable pharmaceutical composition of human calcitonin | |
| ES8800161A1 (en) | Quinolyl glycinamide derivatives, process for their preparation and their pharmaceutical use as psychotropes. | |
| EP0138616A3 (en) | Nona- and dodecapeptides for augmenting natural killer cell activity, processes for making them and pharmaceutical compositions comprising them | |
| MX9604338A (en) | Substituted benzoylguanidines, process for their preparation, its utilization as medicament or diagnosis agent, as well as medicament containing them. | |
| ATE47518T1 (en) | INJECTABLE PHARMACEUTICAL COMPOSITIONS CONTAINING STABLE 5-ADENOSYL-L-METHIONINE SALTS. | |
| ATE288257T1 (en) | DRINKABLE PHARMACEUTICAL SUSPENSION OF IBUPROFEN | |
| ES509468A0 (en) | "PROCEDURE FOR THE PREPARATION OF AQUEOUS SODIUM METHYLINATE SOLUTIONS". | |
| PT93991A (en) | PROCESS FOR THE PREPARATION OF STABLE SOLUTIONS OF REBECAMYCINAL ANALOGS | |
| ES509470A0 (en) | "PROCEDURE FOR THE PREPARATION OF AQUEOUS SODIUM METHYLINATE SOLUTIONS". | |
| KR870008581A (en) | Pharmaceutical Formulations of Stable and Injectable 1,4-Dihydroxy-5,8-bis [2- (2-hydroxyethylamino) ethylamino] anthraquinone, dihydrochloride | |
| DE69529079T2 (en) | FORMULATIONS CONTAINING CODEIN | |
| MX9703839A (en) | Lubeluzole intravenous solutions. | |
| RU98114539A (en) | METHOD FOR EXPERIMENTAL GLAUCOMA MODEL | |
| ES8308927A1 (en) | Lincomycin 3-(5'- ribonucleotides) | |
| RU2000116315A (en) | INTRANASAL ANTISEPTIC |